Vitamin B12: pharmacology, deficiency, replacement and clinical monitoring
On this page
01
Overview
Haematinics • Cobalamin
Vitamin B12 (cobalamin) is essential for DNA synthesis, myelin integrity and red-cell maturation. Deficiency causes megaloblastic anaemia, glossitis and neuropsychiatric disease — and the defining difference from folate deficiency is that B12 deficiency injures the nervous system even when the blood count is normal. Never wait for macrocytosis before considering it.
02
Learning objectives
- Explain intrinsic-factor-dependent absorption.
- Identify dietary and malabsorptive causes and risk groups.
- Distinguish B12 from folate deficiency using clinical and laboratory clues.
- Interpret the investigation pathway, including MMA and intrinsic-factor antibodies.
- Choose oral versus parenteral replacement and monitor neurological recovery safely.
03
Absorption and pharmacology
Food B12 is released in the stomach, binds salivary haptocorrin, then — after pancreatic digestion — binds intrinsic factor (IF) from gastric parietal cells. The IF–B12 complex is absorbed in the terminal ileum, travels on transcobalamin to tissues, and is stored mainly in the liver. Body stores are large, which is why deficiency may take years to appear after absorption fails.
Two enzymes depend on B12: methionine synthase (folate recycling and homocysteine metabolism) and methylmalonyl-CoA mutase — so deficiency raises both homocysteine and methylmalonic acid (MMA).
04
Causes and risk groups
Scroll the table sideways on a smaller screen.
| Cause | Examples | Clinical implication |
|---|---|---|
| Autoimmune malabsorption | Pernicious anaemia, autoimmune gastritis | Intrinsic-factor failure; long-term replacement; review for associated autoimmune disease |
| Gastric causes | Gastrectomy, bariatric surgery, chronic atrophic gastritis | Reduced acid/IF handling; assess lifelong risk |
| Ileal / pancreatic causes | Crohn disease, terminal-ileal resection, coeliac disease, bacterial overgrowth, pancreatic insufficiency | Absorption unreliable; parenteral therapy often required |
| Low intake | Strict unsupplemented vegan diet, food insecurity, frailty | Dietary replacement may succeed if absorption intact |
| Medicine-related | Metformin, acid-suppressing therapy | Review duration and alternatives; do not stop essential medicines without a clinician |
05
Clinical presentation
- Haematological: fatigue, pallor, exertional dyspnoea, macrocytosis, glossitis, mouth ulcers; severe cases add leukopenia and thrombocytopenia.
- Neurological: numbness and tingling, lost vibration and position sense, gait imbalance, weakness, visual change and subacute combined degeneration of the cord.
- Neuropsychiatric: poor concentration, memory change, depression, irritability, psychosis, cognitive decline.
- Paediatric: poor growth, developmental delay or regression in severe deficiency.
06
Diagnosis
Scroll the table sideways on a smaller screen.
| Assessment | Use |
|---|---|
| FBC and film | Macrocytosis, macro-ovalocytes, hypersegmented neutrophils; a normal MCV does not exclude deficiency if iron deficiency or thalassaemia coexist |
| Serum B12 | Initial biochemical test; interpret borderline values with symptoms, medicines and assay limitations |
| MMA ± homocysteine | Helpful in uncertain cases; MMA is specific for B12 deficiency but rises in renal impairment |
| Anti-intrinsic-factor antibodies | Support pernicious anaemia when clinically appropriate |
| Cause investigation | Diet, alcohol, drug and surgical history; assess gastric, ileal and coeliac-disease risk |
Urgent escalation: new gait disorder, rapidly progressive sensory loss, severe weakness, cognitive change, severe anaemia or pancytopenia needs urgent senior assessment and prompt replacement — not routine delayed follow-up.
07
Replacement principles
Oral cyanocobalamin
Appropriate for dietary deficiency and selected patients with intact absorption, using local guidelines with reliable follow-up. High oral doses can be absorbed passively even in some malabsorptive states, but that is a cause-specific decision.
IM hydroxocobalamin
Standard where deficiency is due to malabsorption, pernicious anaemia, significant symptoms or neurological involvement. A NICE-based schedule uses 1 mg IM three times weekly for two weeks without neurological involvement, then maintenance; neurological involvement requires 1 mg IM on alternate days until no further improvement, followed by maintenance. Apply the local protocol — do not copy a schedule blindly.
Maintenance
Irreversible malabsorption usually needs lifelong replacement (commonly 1 mg IM every 2–3 months after repletion); dietary deficiency may allow oral maintenance after stores are restored. Review the cause before stopping injections.
08
Drug summary table
Scroll the table sideways on a smaller screen.
| Preparation | Dose (adult) | Indication | Adverse effects / cautions |
|---|---|---|---|
| Hydroxocobalamin IM | Loading: 1 mg IM 3×/week for 2 weeks (no neurological involvement); neurological involvement: 1 mg IM alternate days until no further improvement. Maintenance: 1 mg IM every 2–3 months | Malabsorption, pernicious anaemia, neurological disease; drug of choice for repletion | Injection-site pain; transient hypokalaemia during early haematological response (potassium shifts into new cells); rare hypersensitivity |
| Cyanocobalamin oral | 50–100 micrograms daily (dietary maintenance); 1–2 mg daily for malabsorption (high-dose oral regimens) | Dietary deficiency; maintenance where absorption intact; selected high-dose oral protocols for malabsorption | Generally very safe; requires adherence and intact follow-up |
| Cyanocobalamin IM | 1 mg IM weekly until corrected, then monthly | Alternative injectable where hydroxocobalamin unavailable | As for hydroxocobalamin |
| Folic acid (companion, not substitute) | 5 mg daily for deficiency; 400 micrograms daily preconceptually/antenatally | Folate deficiency; neural-tube-defect prevention | Never give folate alone in possible B12 deficiency — it can mask the anaemia while neurological injury progresses |
09
Monitoring and counselling
- Baseline: record symptoms and a neurological examination, FBC, B12 ± MMA, and the cause assessment.
- Early response: a reticulocyte rise within days and symptomatic improvement over weeks confirm the diagnosis is behaving; failure suggests wrong diagnosis, mixed deficiency, non-adherence or wrong route.
- Follow-up: FBC/MCV recovery and neurological review — haematology often corrects before nerves, and neurological recovery may be incomplete if treatment is late.
- Long-term: adherence, injection schedule or oral supply, recurrent symptoms, cause-specific review.
Counselling: replacement is usually well tolerated; injection-site reactions, headache, nausea and rare hypersensitivity occur; hydroxocobalamin may discolour urine pink-red temporarily. Report worsening weakness, gait change, numbness, breathlessness, chest pain or allergic symptoms. Dietary improvement helps but cannot replace injections where intrinsic factor or ileal absorption is absent.
10
Clinical scenario
Scenario 1 — Normal Hb, failing nerves
A 62-year-old woman on metformin for six years reports progressive tingling in her feet and unsteadiness in the dark; Hb and MCV are normal. B12 is borderline-low and MMA is elevated — B12 deficiency without anaemia, a classic metformin-associated picture. Treat promptly with IM hydroxocobalamin rather than waiting for macrocytosis, document her neurological deficits at baseline so recovery can be measured, and arrange maintenance therapy. The lesson: the nervous system is the first casualty, not the blood count.
Scenario 2 — The folate trap
A macrocytic patient was given folic acid by a relative; the Hb improved, but his gait has worsened and he now needs support to walk. Urgent assessment confirms severe B12 deficiency with subacute combined degeneration: folate restarted the marrow but did nothing for the cord. Stop folate alone, give IM hydroxocobalamin on the neurological regimen (1 mg alternate days until no further improvement), and counsel that neurological recovery lags haematological recovery and may be incomplete. This is the single most important "never do" in haematinic prescribing.
11
Key points
12
References
- NICE Guideline NG239: Vitamin B12 deficiency in over 16s — diagnosis and management (Library reference.)
- SlideShare: Vitamin B12, folic acid and megaloblastic anaemias (Library reference.)
- Davidson's Principles and Practice of Medicine — megaloblastic anaemias (Library reference.)
- British National Formulary — hydroxocobalamin and cyanocobalamin dosing (Library reference.)
13
Further reading
For deeper study, compare this lesson with current guidance and standard references from recognised medical and public-health organisations.
For education only. Apply current Uganda Clinical Guidelines, local protocols and specialist advice in clinical practice.